研報掘金丨華創證券:通富微電Q4利潤端環比改善顯著,維持“強推”評級
華創證券研報指出,通富微電(002156.SZ)2023年營業收入逐季走高,4季度利潤端環比改善顯著。公司是AMD最大的封裝測試供應商,佔其訂單總數的80%以上,公司積極在檳城擴產備料,未來有望充分受益於AI 浪潮下催生的先進封裝需求增長。此外,公司加強與客户合作,未來優質客户擴容有望帶動公司經營節奏持續向上。考慮到重資產公司稼動率提升對盈利能力的影響,後續行業景氣復甦有望帶動公司盈利能力進一步提升。行業週期觸底反彈,公司優質客户擴容帶動需求增長,後續有望保持穩健增長。維持“強推”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.